IDT Biologika inaugurates its new research and development building in Riems

Greifswald, Germany, 5/29/17

After two years of construction, IDT Biologika is celebrating the opening of its new research and development building at its Riems site in Greifswald. “The new building in Riems is an embodiment of IDT’s dynamic strategy, expanding our manufacturing capacities at the Riems site with a continued focus on outstanding quality. These state-of-the-art laboratories will also allow us to intensify our research for future innovative proprietary products in the animal health field,” says IDT Biologika CEO Dr. Ralf Pfirmann. “Our employees in Mecklenburg-Western Pomerania will be working in cutting-edge jobs and making a significant contribution to IDT’s future.”

Just two years after German Chancellor Angela Merkel laid the cornerstone for the project, IDT Biologika in Riems is inaugurating its new research building with a public ceremony. “We kept to our €10.5 million budget and brought the work in on schedule,” reports Dr. Jörg Köhler, CEO of IDT Biologika (Riems). “Thirty new laboratories with up to 60 work stations have been created on some 1,750 square meters. Both labs and work stations have state-of-the-art equipment and fixtures. Around 50 companies took part in the planning and construction work, in many cases local enterprises from Mecklenburg-Western Pomerania, but also specialized companies from throughout Germany.” Along with 1,400 cubic meters of concrete – according to Dr. Köhler – 125 km of conduits were laid for wiring, electrical installations, computing and building automation. The seven refrigerators and two cold storage cells had to meet the highest quality requirements. While outdoors, 29 trees were planted on the IDT site and surrounding area of Riems.
“IDT Biologika is strongly engaged in research, development and innovation. Innovation is a key driver of sustainable growth and employment. Companies can only take hold in the market with internationally competitive products and services. We need more of these in Mecklenburg-Western Pomerania. That is why we want to strengthen this sector,” announced Harry Glawe, Mecklenburg-Western Pomerania Minister of the Economy, Employment and Health.

IDT Biologika celebrated the inauguration of the new building before the laboratories were cleanroom certified, so that the many guests, including Harry Glawe, Economy Minister for Mecklenburg-Western Pomerania, Prof. Franz J. Conraths, Vice President of the Friedrich Loeffer Institute, and Carsten Klocke, Managing Partner of Klocke Holding, could tour the new labs and facilities.
The ribbon at the entrance to the new IDT Biologika research building in Riems is cut by (from left) Arndt Krug, architect, Carsten Klocke, IDT shareholder, Economy Minister Harry Glawe, IDT CEO Dr. Ralf Pfirmann, IDT Managing Director Andreas Kastenbauer and Dr. Jörg Köhler, CEO IDT Biologika (Riems)
The new IDT Biologika research building in Riems has space for up to 60 new workers.
New IDT Biologika research building in Riems: a look at a virology laboratory with cutting-edge work stations.
About IDT Biologika

IDT Biologika is an innovative, privately-held company with more than 95 years of experience in researching, developing, manufacturing and marketing products for human and animal health. The company produces vaccines and pharmaceuticals according to the highest quality standards, for its own animal health products and under contract. Company sites in Germany include the BioPharmaPark in Dessau-Rosslau and Greifswald. Riems urban district. IDT's Animal Health business is marketed internationally from its offices in Denmark, the Netherlands, France, Spain, Poland and Canada. In the United States, IDT Biologika Corporation operates a production site for clinical test samples for human vaccines in Rockville, Maryland. In Canada, IDT Biologika subsidiary Gallant Custom Laboratories manufactures autogenous vaccines for animals. Autogenous vaccines for animal breeding including global fish farming are also produced by Ridgeway Biologicals, an IDT Biologika subsidiary since January 2017, in Great Britain.

In 2016 IDT Biologika registered sales of €190 million with its two business lines of Animal Health and Contract Manufacturing of vaccines and parenteral products. IDT Biologika currently employs around 1,700 workers.

IDT Biologika is a member of the Klocke Group, which is specialized in contract production and packaging of medications, vaccines and cosmetic products. As a traditional family-owned company, the Klocke Group employs a workforce of more than 2,300 people at nine production sites and sales offices around the world.

Contact

Peter Kellner
Senior Director Global Corporate Communications
Phone +49 34901 885 5681
Mobile +49 162 4248453
peter.kellner@idt-biologika.de

IDT Biologika GmbH
Am Pharmapark, 06861 Dessau-Rosslau, Germany